Boston Sci inks 4-year pact with BHN

Boston Scientific (NYSE: BSX) has expanded its relationship with the privately held Jackson, MS-based Bladder Health Network (BHN), a company that offers advanced testing solutions for urinary incontinence, by signing an exclusive, four-year marketing agreement. The companies had signed a co-marketing deal last September that called for Boston Scientific to start selling BHN's female urinary incontinence diagnostic tool to healthcare providers in the U.S., Mass Device reports.

As part of the agreement, Boston Scientific's Urology and Women's Health Division will market BHN's female urodynamic testing solutions to U.S. healthcare providers. Urodynamics testing uses equipment to measure the amount of pressure experienced by the bladder and urethra in order to evaluate the function and efficiency of a patient's urinary system.

"The agreement with BHN allows Boston Scientific to introduce health care providers to a female continence care platform that offers professional testing and results interpretation," says John Pedersen, SVP and president of Boston Scientific's Urology and Women's Health Division. "This agreement demonstrates Boston Scientific's continuing commitment to the women's health community."

- see the Boston Scientific release
- check out Mass Device's coverage

Suggested Articles

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.